FDA approves revumenib for relapsed or refractory acute ...
On October 24, 2025, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute myeloid leukemia …
Revuforj® (revumenib) | Official Patient Site
Revuforj ® (revumenib) is a prescription medicine used to treat adults and children 1 year and older with: acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation …
Revumenib - Wikipedia
Revumenib, sold under the brand name Revuforj, is an anti-cancer medication used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A) …
Revuforj® (revumenib) Named Best New Drug at the Scrip …
Dec 12, 2025 · Revuforj (revumenib) is an oral, first-in-class menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase …
FDA Approves Revumenib, a Menin Inhibitor, for Aggressive ...
Oct 29, 2025 · Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come …
Dr Stein on the FDA Approval of Revumenib for R/R, NPM1 ...
3 days ago · The approval of revumenib, a menin inhibitor, for patients with NPM1 -mutant relapsed or refractory AML represents a major breakthrough in addressing a critical unmet …
Menin Inhibition With Revumenib for KMT2A -Rearranged ...
Aug 9, 2024 · Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily …
Revumenib Shows Promise for Advanced Acute Myeloid Leukemia
Apr 18, 2023 · The drug, revumenib, is part of a group, or class, of drugs known as menin inhibitors. In an early-phase clinical trial called AUGMENT-101, treatment with revumenib …
Revumenib Uses, Side Effects & Warnings - Drugs.com
Jan 16, 2025 · What is revumenib? Revumenib is used to treat a certain type of acute leukemia in adults and children at least 1 years old. Revumenib is usually given after other treatments did …
Oncology Drug Reference Sheet: Revumenib | Oncology Nursing ...
Jul 29, 2025 · In November 2024, the U.S. Food and Drug Administration (FDA) approved revumenib (Revuforj ®) for relapsed or refractory acute leukemia with a lysine …